April 11, 2024

BioXcel Outlines Trial Design for Agitation in Alzheimer’s Disease Patients

Biopharmaceutical company, BioXcel Therapeutics (Nasdaq: BTAI), has provided details of its upcoming TRANQUILITY In-Care Phase 3 trial which will evaluate BXCL501 as an acute treatment for agitation associated with Alzheimer’s dementia (AAD) in the care setting. BXCL501 is a proprietary, orally dissolving film formulation of dexmedetomidine. “The design of our upcoming TRANQUILITY In-Care trial largely… [Read More]
April 10, 2024

Natural Alternatives (NAII) Is Supplementing Its Supplement Business, Reopening Facility Due to Increase Demand

While many consumer names across all market caps have struggled, the PRISM Consumer Products Index company, Natural Alternatives International Inc. (NAII) has been one of the few who has recently reported positive news that investors have reacted favorably. The company announced it will be reopening its US manufacturing facility in California, due to an increase… [Read More]
April 10, 2024

Inflation Report Dampens Rate Cut Hopes, Shakes Markets and Resets Fed Expectations

Stocks and bonds took a hit as a higher-than-expected inflation report dampened hopes for Federal Reserve interest rate cuts this year. The S&P 500 fell roughly 1% following a consumer price index report that exceeded economists’ predictions for the third consecutive month, exacerbating April’s losses. Ten-year Treasury yields reached a critical 4.5% level, watched closely… [Read More]
April 10, 2024

Neurosense to Evaluate Biological Changes in People with Neurodegenerative Disease

NeuroSense Therapeutics (Nasdaq: NRSN) has announced it will collaborate with Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, to evaluate biological changes occurring in people with neurodegenerative diseases. This agreement will allow NeuroSense to leverage its extensive experience in biomarker utilization in neurodegenerative diseases, while Lonza provides… [Read More]
April 10, 2024

Natera Advances Signatera™ for Bladder Cancer

Natera, Inc. (Nasdaq: NTRA) has reported positive data from its global, double-blind, randomized, Phase 3 IMvigor011 study which is evaluating outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test. Natera’s data demonstrated that MIBC patients who remain Signatera MRD-negative after surgery may… [Read More]
April 10, 2024

YS Biopharma Reports Positive Results in Rabies Vaccine Trial

Global biopharmaceutical company, YS Biopharma (Nasdaq: YS) has announced positive interim results from its ongoing Phase 3 clinical trial of a next-generation PIKA Rabies Vaccine. The vaccine utilizes YS Biopharma’s proprietary PIKA adjuvant technology and is designed to produce a more robust immune response in an accelerated timespan compared to existing rabies vaccines. The interim… [Read More]
April 09, 2024

Palatin Offers Hope to 20 Million Americans with Treatment for Dry Eye Disease

Biopharmaceutical company, Palatin Technologies, Inc. (NYSE American: PTN), has presented positive topline results from its Phase 3 PL9643 MELODY-1 pivotal clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery (ASCRS). Palatin’s study demonstrated clinically meaningful and… [Read More]
April 09, 2024

PRISM Market Moves on Tuesday: BlackBerry Gains on AMD Partnership; ChargePoint, American Express Slide

US equities are trading mostly lower on Tuesday afternoon, with Big tech mostly lower. Outperformers include semis, EVs, precious metals miners, tobacco, chemicals, life sciences, and telecoms, while insurance, credit cards, retail, cruise lines, homebuilders, hotels, airlines, and trucking are weaker. Treasuries are firmer, the Dollar index is flat, Gold is up +0.5%, Bitcoin futures… [Read More]